Activist Shareholder Urges Vote Against Governance Chair, Advocates for Written Consent
Summary
An activist shareholder, John Chevedden, has filed an exempt solicitation urging Deere & Co. shareholders to vote for Proposal 6 (Written Consent) and against Tamra Erwin, Chair of the Governance Committee, citing the company's opposition to shareholder proposals.
Key Events
-
Shareholder Activism
John Chevedden, an activist shareholder, filed an exempt solicitation to rally support for Proposal 6, advocating for shareholder written consent.
-
Director Criticism
The filing explicitly urges shareholders to vote against Tamra Erwin, Chair of the Governance Committee, holding her responsible for the company's opposition to shareholder proposals.
-
Governance Dispute
The activist criticizes Deere's stance on shareholder rights, including its opposition to written consent and its policy on calling special shareholder meetings.
-
Precedent Cited
The filing notes that a similar written consent proposal received 51% support at CDW Corporation in 2025, suggesting potential for success at Deere.
Analysis
This filing highlights escalating shareholder activism at Deere & Co., with a prominent activist directly criticizing the company's governance practices and a specific director. The call for "Written Consent" is a significant shareholder rights proposal, often a flashpoint between management and investors. The explicit recommendation to vote against Tamra Erwin, the Governance Committee Chair, signals deep dissatisfaction with the board's stance on shareholder engagement and corporate democracy. This follows another PX14A6G filing just days ago from a different activist group, indicating broader shareholder pressure. Investors should monitor the upcoming proxy vote closely for the outcome of this proposal and the director's re-election, as it could indicate broader shareholder sentiment regarding the company's governance.
At the time of this filing, DE was trading at $514.42 on NYSE in the Technology sector, with a market capitalization of approximately $139.1B. The 52-week trading range was $404.42 to $533.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.